cbdMD (YCBD) EPS (Basic) (2016 - 2026)

cbdMD (YCBD) posted EPS (Basic) of -$0.04 for Q4 2025, up 78.67% sequentially from -$0.17 in Q3 2025, and up 97.92% YoY from -$0.02 in Q4 2024.

cbdMD (YCBD) EPS (Basic) (2016 - 2026) Analysis & Trends

cbdMD has reported EPS (Basic) for 10 years, with the latest figure at -$0.04 in Q4 2025.

Quarterly EPS (Basic) rose 97.92% year-over-year to -$0.04 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$0.41 (up 96.49% YoY) and the FY2025 annual result came in at -$1.09, up 92.39% from the prior year.
EPS (Basic) rose to -$0.04 in Q4 2025 per YCBD's latest filing, from -$0.17 in the prior quarter.
Over five years, EPS (Basic) peaked at $6.21 in Q2 2021 and troughed at -$198.08 in Q2 2022.
A 5-year average of -$35.29 and a median of -$10.08 in 2023 frame the typical range for EPS (Basic).
The sharpest annual moves came in 2021 and 2022: EPS (Basic) surged 109.78% in 2021, then slumped 3291.57% in 2022.
Over 5 years, EPS (Basic) stood at -$125.53 in 2021, then jumped by 76.45% to -$29.57 in 2022, then jumped by 81.75% to -$5.4 in 2023, then jumped by 67.9% to -$1.73 in 2024, then soared by 97.92% to -$0.04 in 2025.
According to Business Quant data, EPS (Basic) over the past three periods registered -$0.04, -$0.17, and -$0.21 for Q4 2025, Q3 2025, and Q2 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EPS (Basic) (Qtr)
1	Haleon	44.45 Bn	43.48 Bn	-	-
2	Teva Pharmaceutical Industries	43.59 Bn	39.94 Bn	2.15 Bn	-0.49
3	Zoetis	32.51 Bn	30.84 Bn	1.05 Bn	2.07
4	Takeda Pharmaceutical	28.60 Bn	22.81 Bn	5.10 Bn	0.45
5	United Therapeutics	22.04 Bn	19.38 Bn	683.80 Mn	7.82
6	Viatris	19.00 Bn	18.11 Bn	1.46 Bn	-0.10
7	Neurocrine Biosciences	15.53 Bn	15.14 Bn	935.80 Mn	1.43
8	Elanco Animal Health	11.99 Bn	11.46 Bn	798.00 Mn	0.11
9	Dr Reddys Laboratories	10.11 Bn	9.95 Bn	-	-
10	cbdMD	5.38 Mn	3.27 Mn	3.04 Mn	-0.11

Download Data